Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Trading Up 13.5 %

Shares of AVDL Stock traded up $0.70 on Friday, hitting $5.88. 2,274,731 shares of the company's stock traded hands, compared to its average volume of 781,783. The company has a debt-to-equity ratio of 2.11, a quick ratio of 3.65 and a current ratio of 3.65. Avadel Pharmaceuticals has a one year low of $1.05 and a one year high of $11.59. The company's fifty day simple moving average is $3.46 and its 200 day simple moving average is $5.16. The stock has a market capitalization of $347.16 million, a price-to-earnings ratio of -3.82 and a beta of 1.51.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last released its earnings results on Monday, May 9th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). Equities analysts forecast that Avadel Pharmaceuticals will post -1.33 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on AVDL. Oppenheimer lowered their price objective on shares of Avadel Pharmaceuticals to $13.00 in a research report on Friday, May 27th. Craig Hallum lowered their price objective on shares of Avadel Pharmaceuticals from $15.50 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, July 28th. Stifel Nicolaus raised their price objective on shares of Avadel Pharmaceuticals from $2.00 to $5.00 in a research report on Tuesday, July 19th. Needham & Company LLC lowered their price objective on shares of Avadel Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, May 31st. Finally, SVB Leerink lowered their price objective on shares of Avadel Pharmaceuticals from $18.00 to $6.00 and set an "outperform" rating on the stock in a research report on Friday, May 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $9.17.

Insiders Place Their Bets

In other news, Director Eric J. Ende purchased 15,000 shares of the business's stock in a transaction on Tuesday, May 31st. The shares were acquired at an average price of $2.16 per share, with a total value of $32,400.00. Following the acquisition, the director now directly owns 114,900 shares in the company, valued at $248,184. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Eric J. Ende purchased 15,000 shares of the business's stock in a transaction on Tuesday, May 31st. The shares were acquired at an average price of $2.16 per share, with a total value of $32,400.00. Following the acquisition, the director now directly owns 114,900 shares in the company, valued at $248,184. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Thomas S. Mchugh purchased 50,000 shares of the business's stock in a transaction on Friday, May 27th. The stock was purchased at an average cost of $2.14 per share, for a total transaction of $107,000.00. Following the acquisition, the chief financial officer now owns 71,500 shares in the company, valued at $153,010. The disclosure for this purchase can be found here. Insiders have bought a total of 75,000 shares of company stock valued at $155,400 in the last quarter. Insiders own 2.29% of the company's stock.